Crossref
Semaglutide after metabolic and bariatric surgery: advancing treatment for suboptimal weight loss and weight regain
Metabolism and Target Organ Damage · 06.11.2026 · 6 (4)
DOI: 10.20517/mtod.2026.194 ↗Kurz gefasst
Fachartikel in der Zeitschrift Metabolism and Target Organ Damage, online erschienen am 06.11.2026. Verfasst von Audrey White und 1 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
White, A., & McGuire, D. K. (2026). Semaglutide after metabolic and bariatric surgery: advancing treatment for suboptimal weight loss and weight regain. Metabolism and Target Organ Damage, 6(4). https://doi.org/10.20517/mtod.2026.194
Vancouver
White A, McGuire DK. Semaglutide after metabolic and bariatric surgery: advancing treatment for suboptimal weight loss and weight regain. Metabolism and Target Organ Damage. 2026;6(4). doi:10.20517/mtod.2026.194
BibTeX
@article{White2026,
author = {White, Audrey and McGuire, Darren K.},
title = {Semaglutide after metabolic and bariatric surgery: advancing treatment for suboptimal weight loss and weight regain},
journal = {Metabolism and Target Organ Damage},
year = {2026},
volume = {6},
number = {4},
doi = {10.20517/mtod.2026.194}
}
EUVIMED